Sarah Cannon Research Institute | Strategic Alliance Partners

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon in the treatment of patients with myeloproliferative neoplasms.

Stephanie L. Graff, MD, discusses data surrounding escalation and de-escalation in patients with early-stage, hormone receptor–positive breast cancer.

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Cancer Institute, HCA Midwest Health, discusses the patient populations that remain an unmet need in chronic lymphocytic leukemia (CLL).

Suman Kambhampati, MD, reflects on the emergence of data in chronic lymphocytic leukemia from the 2018 ASH Annual Meeting.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses data from the 2018 ASH Annual Meeting in chronic lymphocytic leukemia (CLL).

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses the treatment of patients with newly diagnosed myeloma.

Howard "Skip" A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the impact of molecular profiling in breast cancer.

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses emerging therapies in HER2-positive breast cancer.

Erika P. Hamilton, MD, reflects on the latest data in HER2-positive breast cancer and additional therapies moving through the pipeline.

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the importance of tailoring treatment approaches to the different subtypes of patients with breast cancer.

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses maintenance therapy in multiple myeloma.

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the combination of frontline ibrutinib plus obinutuzumab for the treatment of patients with chronic lymphocytic leukemia.

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the promise of T-DM1 in the treatment of patients with HER2-positive breast cancer.

Denise A. Yardley, MD, discusses key data presented at the 2018 SABCS and the impact of the SOLAR-1 findings.

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses adjuvant therapy for the treatment of patients with HER2-positive breast cancer.

Howard A. “Skip” Burris, MD, highlights some of the exciting updates from the 2018 San Antonio Breast Cancer Symposium and what can be expected in the breast cancer field in the year ahead.

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health, and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the use of tamoxifen in the treatment of patients with breast cancer.

Stephanie L. Graff, MD, discusses the latest updates on escalation and de-escalation of therapy in patients with HR-positive breast cancer.

Erika P. Hamilton, MD, discusses the findings from the phase II nextMONARCH 1 study of abemaciclib in HR-positive, HER2-negative advanced breast cancer.

Ian W. Flinn, MD, PhD, discusses the potential impact of duvelisib on patients with chronic lymphocytic leukemia.

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the addition of biosimilars to breast oncology.

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the FDA approval of talazoparib (Talzenna) for the treatment of patients with germline BRCA mutation–positive, HER2-negative locally advanced or metastatic breast cancer

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, reflects on the results of the PACIFIC trial in patients with non–small cell lung cancer.

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses novel therapies for patients with metastatic breast cancer.

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses combination therapy for the treatment of patients with renal cell carcinoma.

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the RESPECT trial in HER2-positive breast cancer.

Peter J. Van Veldhuizen, MD, hematologist/oncologist, Sarah Cannon Research Institute, discusses frontline immunotherapy for the treatment of patients with kidney cancer.

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, shares insight on the potential impact of biosimilars in breast cancer.

Patients with mutations in NTRK, RET, MET, HER2, and KRAS G12C have limited therapeutic options, but potentially promising agents are on the horizon.